Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0552W HIGH $3.28
Volume
564.62 K
Value Traded
1.20 M
Short % Float
11.59%
-7.76%Week
-26.71%1 Month
-43.39%3 Month
-58.69%6 Month
-76.41%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
71.87 M
EPS (TTM)
-0.24
P/E Ratio
-
Ent. Value
4.50 M
Total Shares
67.17 M
Float Shares
61.03 M
Insiders
9.14%
Institutions
17.26%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
MBOT Catalyst Timeline
Dated clinical, regulatory and corporate events for Microbot Medical Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Microbot Medical Inc.
4Total events
2Upcoming
1Tier-1 (high impact)
2026 to 2026Coverage
Upcoming catalysts 2
Past FDA Catalysts and PDUFA Decisions
How MBOT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Microbot Medical Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every MBOT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| LIBERTY Endovascular Robotic System | 2025-04-09 | 100% success in robotic navigation; 92% reduction in radiation exposure; no adverse events reportedRead More | Microbot Medical Shares Results from Its Pivotal Clinical Trial, Achieving 100% Robotic Navigation Success for the LIBERTY Endovascular Robotic System Successful robotic navigation was achieved in every case and met the Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Stockburger Aileen PtuchaDirector | Grant/Award | 10,000 10,000 held | $0.00 | 04/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MBOT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MBOT for Q2 2026. | ||||
MBOT Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MBOT ranks across every disease it competes in
Competitive Position is a premium feature
See how MBOT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMBOT News
MBOT▼ -4.5%today
Microbot Medical® and Medtechnica Ltd. Enter into Three-Year Exclusive Distribution Agreement in Israel
Microbot Medical has entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market its LIBERTY Endovascular Robotic System in Israel. The agreement follows regulatory approval from the Israeli Ministry of Health, allowing for initial orders expected in Q4 2026. This partnership aims to enhance access to innovative medical technology for healthcare providers in Israel.
Read more →MBOTMicrobot Medical® Highlights Growth Strategy
Microbot Medical Inc. has outlined its growth strategy during an analyst meeting, highlighting high user satisfaction with its LIBERTY System. The company is expanding its sales territories, particularly into California and North Carolina, and is engaging with Value Analysis Committees to facilitate adoption. Plans for international market expansion and improvements in manufacturing processes are also underway, with a focus on achieving positive gross margins by 2027.
Read more →MBOTMicrobot Medical® Among Featured Companies Showcasing Novel Robotic Technologies and Digital Surgery Applications at the Society of Robotic Surgery Annual Meeting
Microbot Medical Inc. will showcase its LIBERTY Endovascular Robotic System at the Society of Robotic Surgery annual meeting from July 23-26 in Fort Lauderdale, FL. The company aims to highlight the growing importance of endovascular robotics in surgical procedures. CEO Harel Gadot will present insights on the endovascular robotic market during the event, which will also feature discussions on emerging technologies in the field.
Read more →MBOTMicrobot Medical® Reports Over 100% Revenue and Customer Growth as Procedure Volume Also Rises in the Second Quarter of 2026
Microbot Medical Inc. reported over 100% growth in revenue and customer acquisition for Q2 2026, driven by the Full Market Release of its LIBERTY System. The company is expanding its U.S. sales territories and has received marketing clearance from Israel. Increased procedure volumes were noted among health systems that adopted the system, indicating rising demand.
Read more →MBOTMicrobot Medical® Increases Manufacturing Capacity as Demand for the LIBERTY® System Rises; Enters into Strategic Agreement with Sanmina, a Global Manufacturing Leader
Microbot Medical has signed a Letter of Agreement with Sanmina Corporation to enhance manufacturing capacity for its LIBERTY Endovascular Robotic System. This partnership aims to support the growing demand in the U.S. and international markets, including recent clearances in Israel. The agreement is expected to improve operational efficiencies and reduce costs as Microbot scales production.
Read more →MBOTMicrobot Medical® Wins Surgical Robotics Industry Award for the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has been awarded the Innovative Start-Up Award by Surgical Robotics Technology for its LIBERTY Endovascular Robotic System. This system is the only FDA-cleared, single-use, remotely operated robotic solution for peripheral endovascular procedures. The award highlights the system's potential to transform healthcare and its growing adoption in leading medical centers.
Read more →MBOTMicrobot Medical® Announces First Health System in Pennsylvania to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that a prominent academic center in Pennsylvania is the first in the state to adopt its LIBERTY Endovascular Robotic System. This adoption marks a significant expansion of the company's presence in the Northeast U.S., joining other health systems in New York City and Boston. The company plans to extend its sales efforts to the West Coast and is also focusing on federal healthcare systems.
Read more →MBOTMicrobot Medical® Enters Into an Agreement to Expand Access for America’s Veteran and Military Patient Populations
Microbot Medical has partnered with Lovell Government Services to enhance access to its LIBERTY Endovascular Robotic System for U.S. veterans and military patients. This collaboration aims to streamline procurement through federal contracting systems, facilitating the availability of advanced medical technologies. The LIBERTY System will be included in Lovell's Federal Supply Schedule, expected to activate in Q3 2026.
Read more →MBOTMicrobot Medical® Announces a Notable Health System as the First in Michigan to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has announced that a leading healthcare system in Michigan is the first in the state to adopt its LIBERTY Endovascular Robotic System. This follows a recent expansion into North Carolina and reflects a growing demand for robotic solutions in vascular care. The LIBERTY System, which is FDA-cleared, aims to enhance procedural workflows and reduce radiation exposure.
Read more →MBOTMicrobot Medical® Secures the First Healthcare System in North Carolina to Adopt the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. has successfully secured its first healthcare system customer in North Carolina for its LIBERTY Endovascular Robotic System. This marks a significant milestone as the company expands its geographic reach, adding to its growing list of health system adopters. CEO Harel Gadot expressed optimism about the company's commercial strategy and future market penetration.
Read more →MBOT▲ +5.8%on this news· ran to +19% by day 3
Microbot Medical Receives Its First International Regulatory Approval for the Commercialization of the LIBERTY Endovascular Robotic becomes the second jurisdiction and the first outside of the U.S. to grant marketing clearance for the LIBERTY System
Microbot Medical has achieved a significant regulatory milestone with Israel granting marketing clearance for its LIBERTY Endovascular Robotic System. This marks Israel as the first country outside the U.S. to approve the system, facilitating commercialization efforts. The approval will allow the company to obtain a Free Sale Certificate for market submissions in other regions. Microbot is also working towards CE Mark certification, aiming to expand its commercial activities into the EU market by the end of 2026.
Read more →MBOTMicrobot Medical to Hold Analysts and Investors Conference Call to Review Recent Progress; Executive Team will be Joined by Current Users of the LIBERTY Endovascular Robotic System, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Inc. is set to hold an analysts and investors conference call on May 18th, focusing on recent progress with its LIBERTY Endovascular Robotic System. During the call, company executives will address claims made in a recent third-party article and clarify misrepresentations. Expert users of the system, Dr. Charles Briggs and Dr. Zachary Bercu, will join to share their experiences with the LIBERTY System, contributing to a discussion aimed at keeping investors accurately informed.
Read more →MBOT▼ -14.7%on this newsshared move
Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026
Microbot Medical Inc. has transitioned to commercial operations, achieving revenue from its limited market release of the LIBERTY Endovascular Robotic System in Q1 of 2026. The company recently initiated a full market release, which has already resulted in revenue exceeding that of the first quarter. Adoption of the LIBERTY System is accelerating, with hospitals across six states adopting the technology and customer orders increasing. Additionally, the company anticipates further growth supported by new industry guidelines and participation in major medical conferences.
Read more →MBOT▼ -14.7%on this newsshared move
Microbot to Hold Conference Call to Review Recent Progress; Executive Team to be Joined by Current LIBERTY Users, Dr. Charles Briggs and Dr. Zachary Bercu
Microbot Medical Inc. (NASDAQ: MBOT) will hold a conference call on May 18th to review the recent progress of the LIBERTY Endovascular Robotic System. The call aims to address inaccuracies made in an unaffiliated third-party article, ensuring the investing public is well-informed. Dr. Charles Briggs and Dr. Zachary Bercu, both users of the LIBERTY System, will share their experiences during the call. This initiative is part of Microbot's efforts to clarify any misleading statements and reinforce its commitment to innovation in endovascular care.
Read more →MBOTLIBERTY Endovascular Robotic System is Now Adopted by Multiple Accounts Across Key Territories Including Two ACCESS-PVI Pivotal Clinical Trial Sites
Microbot Medical's LIBERTY Endovascular Robotic System has gained adoption by multiple accounts, including sites that participated in the ACCESS-PVI pivotal clinical trial, indicating a strong validation of the system's value in clinical settings. The company's ongoing commercial efforts are bolstered by a recent full market release and interest from hospital executives at major medical conferences. Additionally, the upcoming Global Embolization Symposium & Technologies (GEST) conference will provide a platform to further showcase LIBERTY to a broad audience of interventional specialists. However, the company faces challenges related to regulatory approvals and market conditions that could influence future growth.
Read more →MBOTMicrobot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA)
Microbot Medical Inc. has appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia to strengthen its commercial readiness in international markets. The company aims to leverage its FDA-cleared LIBERTY Endovascular Robotic System, expecting CE mark approval by the end of 2026. With the EMEA region presenting substantial growth potential, Microbot seeks to implement a comprehensive sales strategy that enables expansion while maintaining its focus on the U.S. market. The recent successful full market release in the U.S. underscores confidence in the system's adoption and the company's growth strategy.
Read more →MBOTMicrobot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®
Microbot Medical Inc. has welcomed updated occupational protection guidelines from leading medical societies, including SIR and CIRSE. These guidelines aim to lower radiation exposure and improve ergonomic conditions for healthcare practitioners involved in interventional radiology. The LIBERTY System is positioned as a solution to enhance safety and efficiency in these procedures. The endorsement from multiple societies highlights the growing emphasis on protecting healthcare providers.
Read more →MBOTMicrobot Medical® to Highlight Commercial Achievements Leading to the Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System at the 25th Annual Needham Virtual Healthcare Conference
Microbot Medical Inc. will present its recent commercial achievements and the Full Market Release of the LIBERTY Endovascular Robotic System at the Needham Virtual Healthcare Conference. CEO Harel Gadot will discuss the company's strategic positioning and growth opportunities. The LIBERTY system is notable for being the first FDA cleared, single-use robotic system designed to enhance precision in endovascular procedures.
Read more →MBOT▼ -9.3%on this newsshared move
Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting
Microbot Medical Inc. has announced the commencement of its full market release of the LIBERTY Endovascular Robotic System at the Society of Interventional Radiology Annual Scientific Meeting. The system has been adopted by several prominent healthcare systems and is recognized for its precision and efficiency in various procedures. The company aims to expand its sales footprint significantly by the end of 2026.
Read more →MBOTEmory Healthcare Successfully Completes Robotic Peripheral Endovascular Procedures using Microbot Medical®’s LIBERTY® Endovascular Robotic System
Emory Healthcare has successfully utilized Microbot Medical's LIBERTY Endovascular Robotic System for robotic peripheral endovascular procedures, including the first robotic prostate artery embolization for benign prostatic hyperplasia and Y-90 radioembolization mapping for liver cancer. This innovative system aims to improve patient access to high-quality care and enhance procedural efficiency. The LIBERTY System is the only FDA-cleared, single-use, remotely operated robotic system for such procedures.
Read more →About Microbot Medical Inc.
Headquarters25 RECREATION PARK DR SUITE 108, HINGHAM, MA, 02043
BIOPHARMAWATCH ELITE PLUS
Trade the next MBOT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime